
Opinion|Videos|November 20, 2024
Optimizing Regimens and Managing Adverse Events in TIE NDMM
Elizabeth O’Donnell, MD, comments on specific patient subgroups, such as frail or high-risk individuals, who benefit most from particular regimens. She discusses adverse events observed in combination therapies for transplant-ineligible patients with newly diagnosed multiple myeloma and shares her approaches to managing these adverse effects in clinical practice.
Advertisement
Episodes in this series

- Please comment on whether there are specific patient subgroups (eg, frail or high risk) that benefit most from one regimen over the other?
- Please comment on some adverse events observed in combination therapies in transplant-ineligible patients with newly diagnosed multiple myeloma.
- Please address how you manage these adverse effects in clinical practice.
Advertisement
Related to this article

The top 5 OncLive TV videos of the week cover insights in essential thrombocythemia, CML, pancreatic cancer, myelofibrosis, and chronic neutropenia.

Alternating VR-CAP and rituximab plus cytarabine with continuous acalabrutinib produced deep responses and high MRD negativity in untreated MCL.

The FDA approved camizestrant for ESR1-mutated breast cancer, cleared ropeginterferon alfa-2b for essential thrombocythemia, and more.

Dana Chase, MD, discusses why B7-H4 has emerged as a promising antibody-drug conjugate target in ovarian and endometrial cancer.

The FDA approved camizestrant plus a CDK4/6 inhibitor for hormone receptor–positive, HER2-negative metastatic breast cancer that acquires an ESR1 mutation.

Brain cancer experts explain the current wave of surgical advances and advocate for team-based, multidisciplinary strategies to individualize patient care.

Huntsman Cancer Institute at the University of Utah celebrated a major milestone in the development of Huntsman Cancer Institute in Vineyard.
Advertisement
Advertisement
Trending on OncLive
1
Five Under 5: Top Oncology Videos for the Week of 8/31/26
2
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
3
B7-H4–Targeted ADCs Signal a New Frontier for Platinum-Resistant Ovarian and Endometrial Cancer
4
Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC
5


